At which week of pregnancy should growth be monitored every four weeks for patients with Sickle Cell Disease?

Monitoring fetal growth in patients with Sickle Cell Disease is particularly critical due to the increased risk of complications, including fetal growth restriction and preterm birth. At 28 weeks of gestation, the fetal growth pattern and overall health of the fetus can be assessed more accurately, as the majority of fetal growth occurs in the third trimester.

Beginning at this point, it is generally recommended to monitor growth every four weeks to closely track the fetus's development and intervene if any abnormalities are noted. This schedule allows healthcare providers to manage potential complications that can arise due to the mother's condition, ensuring both maternal and fetal health are maintained.

By the time one reaches 20 weeks, the fetus is still in an early growth phase, and the monitoring frequency may not be as crucial as it becomes later in pregnancy. Growth assessments at 32 weeks and beyond are also important; however, the initiation of the regular monitoring schedule at 28 weeks aligns best with the heightened risk profile and growth assessment needs typical of patients with Sickle Cell Disease.